Avandia Advisory Committee: Can Poking Old Wounds Be Good For FDA?
This article was originally published in The Pink Sheet Daily
Two advisory panels will revisit the question of whether FDA should withdraw GlaxoSmithKline’s Avandia from the market as a reevaluation of the cardiovascular trial produces results similar to the original findings; the data does not seem to offer much more clarity, but does give the agency a chance to argue it handled previous controversies well.
You may also be interested in...
A re-adjudication of cardiovascular events in the RECORD trial reassured members of a June 5-6 advisory committee that the study findings are reliable, but did not erase uncertainties about CV risk associated with rosiglitazone.
More than half of a 26-member advisory committee supports eliminating or easing the REMS for GSK’s diabetes drug, but the spilt vote and high-profile of the product’s safety issues suggest that FDA is unlikely to modify Avandia’s risk management.
FDA had only a portion of the information needed to conduct a re-adjudication, Bob Temple tells advisory committee during the first of a two-day discussion of rosiglitizone’s cardiovascular safety.